Want to see SE:BIOEX full AI Analyst Report?

Bioextrax AB (BIOEX) Price & Analysis

0 Followers

BIOEX Stock Chart & Stats

kr3.19

kr0.10(3.70%)

At close: Mar 06 4:00 PM EST

kr3.19

kr0.10(3.70%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.98

Previous CloseN/A

Volume15.49K

Average Volume (3M)66.63K

Market Cap

kr109.96M

Enterprise Valuekr109.23

Total Cash (Recent Filing)kr7.39M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Nov 20, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding47,601,730

10 Day Avg. Volume22,089

30 Day Avg. Volume66,629

Financial Highlights & Ratios

PEG Ratio0.46

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.35

Revenue Forecast (FY)kr1.73M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt capital structure removes scheduled principal repayments and reduces exposure to refinancing or interest-rate shocks. This gives Bioextrax greater financial flexibility to pursue development and commercialization efforts, although it does not eliminate the need to fund ongoing losses.

Fermentation-based PlatformBioextrax’s fermentation-based platform targets microbial-derived ingredients and biopolymers across food, cosmetics, and other industrial uses. This provides a technology foundation that can potentially support several applications and commercialization routes rather than relying on one narrowly defined end product.

Operating Leverage PotentialThe positive gross profit recorded in 2023 indicates that the business has demonstrated some ability to generate favorable product-level economics at least temporarily. If the company can restore and sustain that performance as revenue scales, operating leverage could improve its long-term earnings profile.

Bears Say

Declining RevenueRevenue has contracted in both 2024 and 2025 after stronger performance in 2023, while the reported revenue base remains very small and volatile. Continued weakness in commercial sales would limit scale benefits, reduce resources for development, and make recovery toward sustainable profitability more difficult.

Structural UnprofitabilityPersistent operating and net losses, together with negative gross profit in most years including 2024 and 2025, show that the current cost base is far above the company’s revenue scale. Unless product economics and commercial volumes improve materially, ongoing losses will continue to pressure financial resilience.

Accelerating Cash BurnNegative operating and free cash flow in every reported year means Bioextrax is not currently self-funding its operations. The further deterioration in 2025 increases the likelihood that external capital will be needed, potentially limiting strategic flexibility and increasing dependence on financing availability.

Bioextrax AB News

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 2nd quarter earnings on 08/21/2026. Regarding Q2 estimates, Wall Street analysts...

1M ago

85X0 Earnings this Week: How Will it Perform?

Bioextrax AB (85X0) is scheduled to report 1st quarter earnings on 05/14/2026. Regarding Q1 estimates, Wall Street analysts...

4M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr109.96M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is Nov 20, 2026 which is in 61 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on Aug 21, 2026. The company reported -kr0.1 earnings per share for the quarter, missing the consensus estimate of -kr0.09 by -kr0.01.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is -0.09.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 47,601,730 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -kr0.1 in its last earnings report, missing expectations of -kr0.09. Following the earnings report the stock price went up 0.495%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.